ProPhase Labs (NASDAQ:PRPH) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.37 and traded as high as $0.38. ProPhase Labs shares last traded at $0.36, with a volume of 2,074,714 shares changing hands.

ProPhase Labs Stock Up 8.7%

The company has a debt-to-equity ratio of 0.20, a current ratio of 0.96 and a quick ratio of 0.93. The stock has a fifty day moving average price of $0.37 and a two-hundred day moving average price of $0.37. The company has a market cap of $14.91 million, a P/E ratio of -0.28 and a beta of -0.78.

ProPhase Labs (NASDAQ:PRPH) last posted its earnings results on Wednesday, August 13th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $1.25 million during the quarter, compared to the consensus estimate of $3.55 million. On average, research analysts expect that ProPhase Labs, Inc. will post -1.27 EPS for the current year.

Institutional Trading of ProPhase Labs

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new stake in ProPhase Labs in the fourth quarter worth $40,000. Chapin Davis Inc. grew its position in shares of ProPhase Labs by 60.0% in the first quarter. Chapin Davis Inc. now owns 80,000 shares of the company’s stock valued at $32,000 after purchasing an additional 30,000 shares in the last quarter. Cerity Partners LLC purchased a new position in shares of ProPhase Labs in the first quarter valued at $38,000. XTX Topco Ltd purchased a new position in ProPhase Labs during the second quarter worth about $40,000. Finally, Josh Arnold Investment Consultant LLC purchased a new position in ProPhase Labs during the first quarter worth about $100,000. 9.45% of the stock is owned by hedge funds and other institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.